Melanotan II in Laboratory Research

Melanotan II (MT-II) is a shortened cyclic analog of α-MSH studied for binding at melanocortin receptors (notably MC1R, MC3R, MC4R, MC5R). In research settings, interest centers on receptor occupancy, signaling bias, and comparative pharmacology versus other melanocortin ligands—not on cosmetic endpoints.

Materials sold as research-use-only (RUO) should be evaluated like any other analytical-grade peptide: identity (mass spectrometry), purity (HPLC), and stability documentation from the supplier.

Preclinical literature explores melanocortin pathways involved in energy balance, pigmentation biology, and sexual function models—often as probe compounds rather than drug candidates. MT-II’s promiscuity across receptor subtypes makes it a tool for dissecting pathway redundancy in controlled assays.

Researchers typically pair ligand data with receptor mutagenesis, β-arrestin recruitment assays, or in vivo telemetry in approved animal protocols. Those designs do not translate to informal human experimentation.

• Identity: high-resolution mass confirmation of the expected sequence and cyclization pattern.
• Purity: HPLC trace with integration thresholds clearly stated.
• Endotoxin / sterility: relevant only when the experimental design requires it—document what was actually tested.
• Stability: lyophilized storage, reconstitution solvent, and hold-time limits per institutional SOP.

MT-II is not an FDA-approved drug for cosmetic or wellness use. RUO catalog listings are intended for qualified laboratories. Jurisdictions differ on how enforcement treats non-clinical sales; see peptide legality overview for general framing.

PurePep Vital does not sell peptides. When comparing retailer documentation for planning experiments, the Melanotan II deal profile summarizes current Live Alpha Labs routing and code SOL disclosure.

Both ligands touch melanocortin pharmacology, but PT-141 (bremelanotide) has a distinct clinical development history and receptor selectivity profile compared with MT-II’s broader agonism. For receptor-level comparisons, see PT-141 research overview and keep compounds analytically separated in study design.

For endocrine cluster context, browse hormone research peptides. For fundamentals, what are peptides and RUO standards primer. Commercial evaluation should always return to batch COAs and institutional safety review.